SCHEMBL15511374

SCHEMBL15511374

CS(=O)(=O)c1ccc(OC[C@H]2CC[C@H](N3CCN(C(=O)O)CC3)CC2)cc1Cl

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TRPV4 Q9HBA0 1/20 0.41
▸ HRH3 Q9Y5N1 4/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ SLC6A2 P23975 2/20 0.40
▸ SLC6A4 P31645 2/20 0.40
▸ SLC6A3 Q01959 2/20 0.40
▸ GPR119 Q8TDV5 1/20 0.39
▸ HRH1 P35367 1/20 0.39
▸ CCR3 P51677 1/20 0.39
▸ THRB P10828 1/20 0.39
▸ F2 P00734 3/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ DRD2 P14416 1/20 0.39
▸ ADRA1D P25100 1/20 0.39
▸ ADRA1A P35348 1/20 0.39
▸ ADRA1B P35368 1/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15511375 1.00 TRPV4 (0.41) TRPV4HRH3NPC1RAB9ASLC6A2
SCHEMBL15495659 0.88 GPR119 (0.54) GPR119
SCHEMBL13733218 0.88 GPR119 (0.54) GPR119
SCHEMBL15511694 0.81 SLC6A9 (0.50) NPC1RAB9AHRH1CCR3SMN1; SMN2
SCHEMBL15511693 0.81 SLC6A9 (0.50) NPC1RAB9AHRH1CCR3SMN1; SMN2
SCHEMBL2430940 0.79 GPR119 (0.62) GPR119AOC2
SCHEMBL15511339 0.76 SIGMAR1 (0.54) HRH3SLC6A4
SCHEMBL15511340 0.76 SIGMAR1 (0.54) HRH3SLC6A4
SCHEMBL15511762 0.75 SLC6A9 (0.59) GPR119DRD2ADRA1DADRA1AADRA1B
SCHEMBL15511763 0.75 SLC6A9 (0.59) GPR119DRD2ADRA1DADRA1AADRA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140066369-A1 Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto ARENA PHARMACEUTICALS, INC. (US) 2014-03-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140066369-A1 Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto GPR119, GLP1R, SLC5A2 TRPV4 227/4885HRH3 2447/4885NPC1 424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback